Hims & Hers Stock Retreats as Peptide Market Optimism Fades

Hims & Hers stock briefly rallied on reports the FDA may ease peptide restrictions, but gains reversed on regulatory uncertainty. The company is strategically positioned with a new production facility.

A recent report suggesting the U.S. Food and Drug Administration (FDA) may ease restrictions on certain injectable peptides provided only a fleeting boost to shares of telemedicine provider Hims & Hers. The initial investor enthusiasm, sparked by the company's strategic positioning in this niche, quickly gave way to a sober assessment of market realities and regulatory uncertainties.

Regulatory Shift Presents a Strategic Opportunity

The catalyst was a New York Times report indicating the FDA plans to rescind a manufacturing ban on more than a dozen injectable peptides. This follows an announcement in late February by Health Secretary Robert F. Kennedy Jr. to reallow approximately 14 previously restricted substances for use by licensed compounding pharmacies.

This potential regulatory opening aligns with a strategic move Hims & Hers made earlier this year. In February 2025, the company proactively acquired a peptide production facility in California. Management confirmed during a recent earnings call that it is actively developing a related product line. Market researchers at PitchBook note that a legal, regulated distribution channel would protect consumers from turning to potentially unsafe gray markets overseas for these substances.

A Brief Rally Meets Sustained Selling Pressure

The prospect of accessing a new market initially sent the stock soaring more than seven percent on Tuesday. These gains proved entirely temporary. By Wednesday, sentiment had reversed sharply. After opening higher, shares declined 3.88 percent, closing near the session's low at $20.06.

The equity remains under significant selling pressure. Trading below its key 20-, 50-, and 200-day moving averages, the broader technical chart picture remains bearish. Year-to-date, the stock is down approximately 33 percent.

Diversifying Beyond Weight-Loss Injectables

The push into peptides serves as a strategic hedge for Hims & Hers. The company's business involving compounded GLP-1 weight-loss drugs previously faced regulatory scrutiny, which ultimately led to a partnership with Novo Nordisk to distribute branded medications like Wegovy.

While the anticipated FDA relaxation offers a potential new revenue stream, significant uncertainties persist. The Department of Health has not provided a concrete timeline for the reclassification of these substances. Furthermore, even if the rules change, these peptides would not become officially approved drugs but would remain off-label therapies requiring a physician's prescription and monitoring. Market observers anticipate continued high volatility and expect the stock to trade sideways within a range of $18.00 to $21.50 until the regulatory changes are concretely implemented.